Ian Hodgson
Known title: Chief Operating OfficerCIK: 0002057525
Associated companies
Transaction History
| CRBP | ▼ Sell | Open Market | 847 | $6K | 2/17/2026 | View on chart |
| CRBP | ▼ Sell | Open Market | 2,415 | $20K | 2/3/2026 | View on chart |
| CRBP | ▲ Buy | Grant | 28,365 | $0 | 1/14/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Corbus Doses First Patient in CRB-701 TEMPO-1 Study
Corbus Pharmaceuticals announced that the first patient has been dosed in the TEMPO-1 registrational study for CRB-701. This clinical trial focuses on patients with second-line or later oropharyngeal cancer. The update marks a significant step in the development timeline for the company's lead asset.
Corbus Doses First Patient in CRB-701 TEMPO-1 Study. Corbus Pharmaceuticals announced that the first patient has been dosed in the TEMPO-1 registrational study for CRB-701. This clinical trial focuses on patients with second-line or later oropharyngeal cancer. The update marks a significant step in the development timeline for the company's lead asset.